AKT1 and breast carcinoma: Cumulative data from clinical studies support the hypothesis that Akt hyperphosphorylation in breast cancer predicts a worse outcome among endocrine‐treated patients (Perez‐Tenorio & Stal, 2002; Osborne & Schiff, 2011).